Management of Hypercalcemia in Adults

Initial Assessment and Severity Stratification

• Hypercalcemia is classified by corrected serum calcium: mild < 12 mg/dL (3 mmol/L), moderate‑to‑severe ≥ 12 mg/dL (≥ 3 mmol/L), and severe > 14 mg/dL (> 3.5 mmol/L). Treatment should be initiated when calcium exceeds 12 mg/dL (3 mmol/L)【@5】.
• Moderate‑to‑severe hypercalcemia commonly presents with polyuria, polydipsia, nausea, confusion, vomiting, abdominal pain, and myalgia【@3】【@4】.
• Severe hypercalcemia can cause mental status changes, bradycardia, hypotension, somnolence, and coma【@3】.

First‑Line Hydration (All Patients)

• Administer intravenous normal saline to achieve urine output > 2.5 L/day; this promotes calciuresis and corrects hypovolemia【@5】.
• Crystalloid fluids without calcium are essential for restoring intravascular volume and enhancing renal calcium excretion【@3】【@6】.
• Oral hydration may be sufficient for mild hypercalcemia, but intravenous fluids remain the cornerstone for higher severity levels【@3】【@4】.
• Loop diuretics (e.g., furosemide) should be used only after adequate volume repletion to avoid worsening dehydration【@3】【@4】.

Antiresorptive Therapy

Bisphosphonates

• Zoledronic acid 4 mg IV infused over 15 minutes in 100 mL is the preferred bisphosphonate for moderate‑to‑severe hypercalcemia, limiting renal toxicity【@1】【@5】【@2】.
• Zoledronic acid normalizes calcium in ≈ 50 % of patients by day 4, compared with ≈ 33 % for pamidronate【@6】.

• Alternative bisphosphonates include pamidronate 90 mg IV (2 h infusion) and ibandronate【@1】【@5】.
• An 8‑mg dose of zoledronic acid is reserved for relapsed or refractory hypercalcemia【@5】【@6】【@7】.

Denosumab

• Subcutaneous denosumab 120 mg is effective, especially in bisphosphonate‑refractory cases, lowering calcium in 64 % of such patients within 10 days【@6】【@7】.
• Denosumab is preferred for patients with renal impairment because it carries a lower risk of renal toxicity than zoledronic acid【@1】【@2】.
• Post‑administration monitoring for hypocalcemia is required; calcium and vitamin D supplementation should be provided as needed【@6】【@7】.

Adjunctive Therapies (Based on Etiology & Severity)

• Calcitonin can be added to bisphosphonate or denosumab regimens for rapid, short‑term calcium reduction in severe or rapidly evolving hypercalcemia【@1】【@2】【@4】.
• Glucocorticoids are first‑line when hypercalcemia results from vitamin D intoxication, granulomatous disease (e.g., sarcoidosis), or certain lymphomas; they are also incorporated into treatment of multiple‑myeloma‑related hypercalcemia【@3】【@4】【@1】【@2】.

Monitoring Requirements

• Bisphosphonate therapy: check serum creatinine, urea, total calcium, and urinary albumin before and during treatment; discontinue bisphosphonates if unexplained albuminuria > 500 mg/24 h, serum creatinine rise > 0.5 mg/dL, or absolute creatinine > 1.4 mg/dL in patients with normal baseline【@5】.
• Denosumab therapy: monitor serum calcium after each dose due to higher hypocalcemia risk; provide calcium/vitamin D as needed【@6】【@7】.

Special Populations

Malignancy‑Related Hypercalcemia

• Occurs in 10–25 % of cancer patients and is associated with a median survival of ≈ 1 month in lung cancer【@3】【@4】.

Multiple Myeloma

• Management includes hydration, bisphosphonates (preferably zoledronic acid), denosumab, steroids, and/or calcitonin【@1】【@2】.

Common Pitfalls to Avoid

• Do not give loop diuretics before adequate volume repletion, as this can exacerbate dehydration【@3】【@4】.
• Do not use bisphosphonates without prior hydration; IV fluids are essential first‑line therapy【@5】【@6】.
• Avoid overly rapid correction of chronic severe hypercalcemia to prevent complications, although this is less critical than in hyponatremia【@6】.
• Monitor renal function closely during bisphosphonate therapy because nephrotoxicity can occur at any time【@5】.